These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27339303)

  • 1. Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial.
    Anyanwu JN; Williams O; Sautter CL; Kasirye P; Hume H; Opoka RO; Latham T; Ndugwa C; Ware RE; John CC
    JMIR Res Protoc; 2016 Jun; 5(2):e110. PubMed ID: 27339303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
    Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
    Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia.
    Jeste ND; Sánchez LM; Urcuyo GS; Bergés ME; Luden JP; Stuber SE; Latham TS; Mena R; Nieves RM; Ware RE
    JMIR Res Protoc; 2017 Jun; 6(6):e107. PubMed ID: 28576754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
    N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial.
    McGann PT; Tshilolo L; Santos B; Tomlinson GA; Stuber S; Latham T; Aygun B; Obaro SK; Olupot-Olupot P; Williams TN; Odame I; Ware RE;
    Pediatr Blood Cancer; 2016 Jan; 63(1):98-104. PubMed ID: 26275071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.
    McGann PT; Williams TN; Olupot-Olupot P; Tomlinson GA; Lane A; Luís Reis da Fonseca J; Kitenge R; Mochamah G; Wabwire H; Stuber S; Howard TA; McElhinney K; Aygun B; Latham T; Santos B; Tshilolo L; Ware RE;
    Am J Hematol; 2018 Aug; 93(4):537-545. PubMed ID: 29318647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia.
    Rankine-Mullings AE; Little CR; Reid ME; Soares DP; Taylor-Bryan C; Knight-Madden JM; Stuber SE; Badaloo AV; Aldred K; Wisdom-Phipps ME; Latham T; Ware RE
    JMIR Res Protoc; 2016 Sep; 5(3):e185. PubMed ID: 27619954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS): study protocol for a randomized placebo-controlled trial in Ugandan children with sickle cell anemia.
    Datta D; Namazzi R; Conroy AL; Cusick SE; Hume HA; Tagoola A; Ware RE; Opoka RO; John CC
    Trials; 2019 Jul; 20(1):460. PubMed ID: 31349866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
    N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia.
    Carman AS; Sautter C; Anyanwu JN; Ssemata AS; Opoka RO; Ware RE; Rujumba J; John CC
    Pediatr Blood Cancer; 2020 Feb; 67(2):e27830. PubMed ID: 31135090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea therapy for sickle cell anemia.
    McGann PT; Ware RE
    Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa.
    Olupot-Olupot P; Tomlinson G; Williams TN; Tshilolo L; Santos B; Smart LR; McElhinney K; Howard TA; Aygun B; Stuber SE; Lane A; Latham TS; Ware RE
    Blood; 2023 Mar; 141(12):1402-1410. PubMed ID: 36375125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease.
    Smart LR; Segbefia CI; Latham TS; Stuber SE; Amissah-Arthur KN; Dzefi-Tettey K; Lane AC; Dei-Adomakoh YA; Ware RE
    Trials; 2023 Sep; 24(1):603. PubMed ID: 37737189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial.
    Abdullahi SU; Wudil BJ; Bello-Manga H; Musa AB; Gambo S; Galadanci NA; Aminu H; Tijjani Gaya A; Sanusi S; Tabari MA; Galadanci A; Borodo A; Abba MS; Dambatta AH; Haliru L; Gambo A; Cassell H; Rodeghier M; Ghafuri DL; Covert Greene BV; Neville K; Kassim AA; Kirkham F; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
    Pediatr Hematol Oncol; 2021 Feb; 38(1):49-64. PubMed ID: 33236662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial.
    Namazzi R; Opoka R; Conroy AL; Datta D; Tagoola A; Bond C; Goings MJ; Ryu MS; Cusick SE; Krebs NF; Jang JH; Tu W; Ware RE; John CC
    Blood Adv; 2023 Jul; 7(13):3023-3031. PubMed ID: 36735400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens.
    Teigen D; Opoka RO; Kasirye P; Nabaggala C; Hume HA; Blomberg B; John CC; Ware RE; Robberstad B
    Pharmacoeconomics; 2023 Dec; 41(12):1603-1615. PubMed ID: 37462838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda (BRAIN SAFE II): Protocol for a single-arm open label trial.
    Mboizi V; Nabaggala C; Munube D; Ssenkusu JM; Kasirye P; Kamya S; Kawooya MG; Boehme A; Minja F; Mupere E; Opoka R; Rosano C; Green NS; Idro R
    medRxiv; 2024 Jan; ():. PubMed ID: 38260320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania.
    Makubi A; Sasi P; Ngaeje M; Novelli EM; Mmbando BP; Gladwin MT; Makani J
    BMC Med Res Methodol; 2016 Oct; 16(1):140. PubMed ID: 27756209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial.
    Hood AM; Strong H; Nwankwo C; Johnson Y; Peugh J; Mara CA; Shook LM; Brinkman WB; Real FJ; Klein MD; Hackworth R; Badawy SM; Thompson AA; Raphael JL; Yates AM; Smith-Whitley K; King AA; Calhoun C; Creary SE; Piccone CM; Hildenbrand AK; Reader SK; Neumayr L; Meier ER; Sobota AE; Rana S; Britto M; Saving KL; Treadwell M; Quinn CT; Ware RE; Crosby LE
    JMIR Res Protoc; 2021 May; 10(5):e27650. PubMed ID: 34018965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea mobile directly observed therapy versus standard monitoring in patients with sickle cell anemia: a phase 2 randomized trial.
    Sasi P; Makubi A; Sangeda RZ; Ngaeje MY; Mmbando BP; Soka J; Rosano C; Magesa AS; Cox SE; Makani J; Novelli EM
    Commun Med (Lond); 2024 Aug; 4(1):160. PubMed ID: 39122788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.